GSK 2800528

Drug Profile

GSK 2800528

Alternative Names: GSK2800528

Latest Information Update: 14 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation; Psoriasis

Most Recent Events

  • 01 Apr 2014 GlaxoSmithKline completes a phase I trial in Inflammation and Psoriasis (in volunteers) in United Kingdom (NCT01899755)
  • 31 Jul 2013 Phase-I clinical trials in Inflammation (in volunteers) in United Kingdom (SC)
  • 31 Jul 2013 Phase-I clinical trials in Psoriasis (in volunteers) in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top